Spleen-Targeted Glabridin-Loaded Nanoparticles Regulate Polarization of Monocyte/Macrophage (M<sub>o</sub> /M<sub>φ</sub> ) for the Treatment of Cerebral Ischemia-Reperfusion Injury.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 35973230.
- Also identified by DOI 10.1002/adma.202204976 and PMC identifier 9594991.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
During cerebral ischemia-reperfusion (I-R) injury, the infiltration of monocyte/macrophages (M<sub>o</sub> /M<sub>φ</sub> ) into the ischemic penumbra causes inflammatory damage but also regulates tissue repair in the penumbra. The regulation and balance of M<sub>o</sub> /M<sub>φ</sub> polarization is considered as a potential therapeutic target for treating cerebral I-R injury. Herein, these findings demonstrate that glabridin (Gla)-loaded nanoparticles (i.e., NP<sub>Gla</sub> -5k) can effectively inhibit M1-polarization and enhance M2-polarization of M<sub>o</sub> /M<sub>φ</sub> . Positron emission tomography (PET) imaging shows that NP<sub>Gla</sub> -5k can selectively accumulate in the spleen following intravenous injection. Spleen-targeted Cy5-NP<sub>Gla</sub> -5k can co-localize with peripheral macrophages in the penumbra at 24 h after tail-vein injection. Interestingly, NP<sub>Gla</sub> -5k treatment can reduce inflammatory damage, protect dying neurons, and improve nervous system function. The protective effect of spleen-targeted NP<sub>Gla</sub> -5k against cerebral I-R injury in mice encourages an exploration of their use for clinical treatment of patients with cerebral I-R injury.
Medical subject headings
- Nanoparticles
- Reperfusion Injury